VXRT Stock Chart & Stats
$12.00
$0.00(0.00%)
At close: 4:00 PM EDT
$12.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$12.00 - $12.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$2.00B
Enterprise Value$95.07
Total Cash (Recent Filing)$63.98M
Total Debt (Recent Filing)$7.81M
Price to Earnings (P/E)3.3
Beta-0.19
Next Earnings
Oct 29, 2026EPS Estimate
-2.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding242,835,360
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.92
Price to Sales (P/S)0.34
P/FCF Ratio10.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.48
Revenue Forecast (FY)$3.44B
Bulls Say, Bears Say
Bulls Say
European Intellectual-property Protection For Oral Norovirus VaccineThe European patent strengthens Vaxart’s defensibility in oral norovirus vaccines and protects core room-temperature-stable, needle-free technology for many years. Broad geographic coverage can support future partnering, preserve commercialization options, and increase the platform’s strategic value.
Improved Profitability And Cash GenerationThe TTM profitability and positive operating and free cash flow represent a substantial improvement from consistently negative cash generation during 2021–2024. If sustained, this earnings quality can support research investment, reduce reliance on external capital, and improve financial resilience.
Large, Fully Enrolled Phase IIb Trial Supported By BARDA FundingFull enrollment creates a defined clinical catalyst with a substantially larger evidence base than the sentinel cohort, while BARDA funding supports completion and deeper mucosal, genomic, and cellular analyses. Positive results could materially validate Vaxart’s oral vaccine platform and partnering prospects.
Bears Say
Sharp Year-over-year Revenue ContractionThe sharp quarterly revenue decline indicates that current revenue streams are not consistently expanding and may remain dependent on contract or collaboration activity. Sustained contraction would weaken internal funding capacity, reduce operating leverage, and make development progress more reliant on financing or partners.
Cash Runway Creates Financing And Dilution PressureA runway only into Q2 2027 leaves limited financial flexibility relative to the timing of major clinical readouts and ongoing development needs. If partner or non-dilutive funding does not arrive promptly, additional equity financing could dilute shareholders or force spending reductions that delay execution.
Early Efficacy Evidence Remains InconclusiveThe clean safety results do not yet establish that the oral vaccine provides superior or comparable efficacy, because the sentinel cohort was designed for safety and showed similar infection counts between arms. This leaves the platform’s clinical differentiation dependent on the larger H1 2027 readout.
Vaxart News
VXRT FAQ
What was Vaxart Inc’s price range in the past 12 months?
Vaxart Inc lowest stock price was $12.00 and its highest was $12.00 in the past 12 months.
What is Vaxart Inc’s market cap?
Vaxart Inc’s market cap is $2.00B.
When is Vaxart Inc’s upcoming earnings report date?
Vaxart Inc’s upcoming earnings report date is Oct 29, 2026 which is in 44 days.
How were Vaxart Inc’s earnings last quarter?
Vaxart Inc released its earnings results on Aug 06, 2026. The company reported -$1.024 earnings per share for the quarter, beating the consensus estimate of -$2.048 by $1.024.
Is Vaxart Inc overvalued?
According to Wall Street analysts Vaxart Inc’s price is currently Overvalued.
Does Vaxart Inc pay dividends?
Vaxart Inc does not currently pay dividends.
What is Vaxart Inc’s EPS estimate?
Vaxart Inc’s EPS estimate is -2.9.
How many shares outstanding does Vaxart Inc have?
Vaxart Inc has 242,835,360 shares outstanding.
What happened to Vaxart Inc’s price movement after its last earnings report?
Vaxart Inc reported an EPS of -$1.024 in its last earnings report, beating expectations of -$2.048. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vaxart Inc?
Currently, no hedge funds are holding shares in MX:VXRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxart Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vaxart Inc
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
VXRT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced mix of encouraging clinical and operational developments alongside material financial and timing risks. Key positives include a clean 12‑month safety signal in the sentinel cohort, BARDA’s $29 million contract modification enabling deeper analyses, a fully enrolled ~5,000‑participant main cohort with topline expected H1 2027, governance improvements, and a defined cash runway with flexible financing options. Offsetting these are a ~31.5% year‑over‑year revenue decline, a limited cash runway into Q2 2027 that creates timing pressure for funding or partner opt‑ins, reliance on BARDA for data release timing, uncertainty around the norovirus partnership and development timelines, and that the sentinel cohort was not powered to demonstrate efficacy (symptomatic case counts were similar between arms). On balance, positives (safety readout, BARDA support, large main cohort enrollment, governance actions) are meaningful but are matched by significant near‑term financing and commercialization uncertainties; the overall tone is constructive but cautious.View all MX:VXRT earnings summaries